Business description
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Management board & Supervisory board
| CEO |
| Robert Bradway |
| Management board |
| Peter H. Griffith, Annalisa Pizzarello, Anton Rabushka, Arleen Paulino, Darryl Sleep, David A. Piacquad, David M. Reese, Esteban Santos, Gilles Marrache, Ian Thompson, Jean-Charles Soria, Jerry Murry, Jonathan Graham, Judy Gawlik Brown, Lori Johnston, Mark J. Taisey, Mike Zahigian, Murdo Gordon, Nancy Grygiel, Rachna Khosla, Raymond Deshaies, Rob Lenz, Susan Sweeney, Victoria H. Blatter |
| Supervisory board |
| Robert A. Bradway, Amy E. Miles, Ellen J. Kullman, R. Sanders Williams, Ronald D. Sugar, Wanda M. Austin, Michael V. Drake, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Charles M. Holley Jr., S. Omar Ishrak, Tyler Jacks |
Company data
| Name: |
Amgen Inc. |
| Address: |
One Amgen Center Drive,Thousand Oaks, CA 91320-1799, USA |
| Phone: |
+1-805-447-1000 |
| Fax: |
+1-805-447-1010 |
| E-mail: |
investor.relations@amgen.com
|
| Internet: |
www.amgen.com |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12-31 |
| Free Float: |
76.20% |
| IPO date: |
1983-06-17 |
